( Friday close ) Chart courtesy of stockcharts

Shares of Amgen are trading down today after company late Friday said an interim Phase III study found no significant improved response for chemotherapy patients taking Aranesp from those who weren't. Looking at the daily chart, stock has been recovering from the losses occurred since the start of November. MACD fast line already crossed slow line, indicating that the sentiment improved and a perspective for a new rebound should be in place, so keep an eye on AMGN for a possible breakout over its 50 dma.

Disclaimer : Trading stocks involves risk, this information should not be viewed as trading recommendations.The charts provided here are not meant for investment purposes and only serve as technical example.